NJH-2-056 is a DUBTAC rather than a classical degradative PROTAC. Public sources describe it as a deubiquitinase-targeting chimera that links the OTUB1 recruiter EN523 to the CFTR corrector lumacaftor. Its functional design is opposite to conventional PROTAC-mediated degradation: the CFTR-binding portion targets the ΔF508-CFTR chaperone-associated protein complex, while the OTUB1-recruiting element brings a deubiquitinase into proximity to stabilize the target protein. Mechanistically, NJH-2-056 is intended to reduce ubiquitin-dependent turnover and increase CFTR protein stability rather than induce proteasomal destruction. It is useful for studying targeted protein stabilization, deubiquitinase recruitment, CFTR folding and trafficking biology, comparison of DUBTACs with PROTACs, and broader induced-proximity strategies that either remove or rescue disease-relevant proteins.
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Target: Targets BRD4 and BET bromodomain proteins for experimental targeted protein degradation studies.
Binding Site: Binds the BET acetyl-lysine recognition pocket and cereblon thalidomide-binding domain to support productive ternary complex formation.
Mechanism of Action: NJH-2-056 is designed for use in PROTAC or targeted protein degradation experiments directed toward BRD4 and BET bromodomain proteins. The bifunctional molecule links a target-recognition element to cereblon, promoting proximity between the protein of interest and ubiquitination machinery. Productive ternary-complex formation can drive polyubiquitination and proteasome-dependent target depletion, allowing researchers to compare pharmacological inhibition with protein removal. It is suitable for evaluating degradation potency, kinetics, pathway selectivity, and downstream signaling consequences in engineered or disease-relevant cellular models.
Applications• PROTAC-Mediated Oncogenic Protein Degradation: NJH-2-056 can be employed in research to selectively degrade oncogenic proteins, thereby elucidating their role in cancer cell proliferation and survival. This approach aids in identifying potential therapeutic targets by observing changes in cell viability upon targeted protein degradation.
• Targeted Degradation in Neurodegenerative Disease Models: Researchers can utilize NJH-2-056 to study the degradation of proteins implicated in neurodegenerative diseases. This application allows for the exploration of protein turnover and aggregation processes, providing insights into disease pathology and potential intervention points.
• PROTAC-Driven Signal Transduction Analysis: NJH-2-056 facilitates the degradation of key signaling proteins, enabling the dissection of complex signal transduction pathways. By observing the effects of protein removal on downstream signaling, researchers can better understand pathway dynamics and identify critical regulatory nodes.
• Investigating Protein Stability and Function: NJH-2-056 serves as a tool for probing protein stability and function by inducing selective degradation. This application helps delineate the functional landscape of target proteins, contributing to a deeper understanding of their role in cellular processes and disease mechanisms.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.